Protalix BioTherapeutics, Inc.
PLX
Rank in Stocks
#16495
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the... Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a plant cell expressed recombinant PEGylated Uricase, which is in Phase 2 trial for the treatment of gout; and PRX-119, a plant cell expressed PEGylated recombinant human DNase I product candidate for the treatment of neutrophil extracellular traps diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz; and Chiesi Farmaceutici S.p.A. Protalix BioTherapeutics, Inc. has strategic partnership with Secarna Pharmaceuticals GmbH & Co KG. The company is headquartered in Hackensack. New Jersey.
Share Price
$2.57
Last synced: 2026-11-09
Market Cap
$207.07M
Change (1 day)
1.18%
Change (1 year)
20.66%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Protalix BioTherapeutics, Inc. (PLX)
Category
Healthcare
EPS for Protalix BioTherapeutics, Inc. (PLX)
EPS as of June 2026 TTM: $0.24
According to Protalix BioTherapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $0.24. At the end of 2025 the company had an EPS of $-0.08, a decrease compared to its 2024 EPS of $0.04.
EPS history for Protalix BioTherapeutics, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.24 | -400.00% |
| 2025 | $-0.08 | -308.17% |
| 2024 | $0.04 | -66.33% |
| 2023 | $0.12 | -138.71% |
| 2022 | $-0.31 | -50.00% |
| 2021 | $-0.62 | 181.82% |
| 2020 | $-0.22 | -82.11% |
| 2019 | $-1.23 | -31.67% |
| 2018 | $-1.80 | -72.31% |
| 2017 | $-6.50 | 2,141.38% |
| 2016 | $-0.29 | -147.54% |
| 2015 | $0.61 | -290.63% |
| 2014 | $-0.32 | 6.67% |
| 2013 | $-0.30 | -76.92% |
| 2012 | $-1.30 | -69.77% |
| 2011 | $-4.30 | 1,094.44% |
| 2010 | $-0.36 | -12.20% |
| 2009 | $-0.41 | 36.67% |
| 2008 | $-0.30 | -91.04% |
| 2007 | $-3.35 | 946.88% |
| 2006 | $-0.32 | -89.68% |
| 2005 | $-3.10 | 138.46% |
| 2004 | $-1.30 | 170.83% |
| 2003 | $-0.48 | -5.88% |
| 2002 | $-0.51 | -50.00% |
| 2001 | $-1.02 | 292.31% |
| 2000 | $-0.26 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 6,425.00% |
US
|
|
| $-7.07 | -3,045.83% |
US
|
|
| $-5.29 | -2,304.17% |
AU
|
|
| $12.88 | 5,266.71% |
BE
|
|
| $21.56 | 8,883.33% |
NL
|
Questions about Protalix BioTherapeutics, Inc.'s earnings per share (EPS)
What is Protalix BioTherapeutics, Inc.'s earnings per share (EPS)?
Protalix BioTherapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $0.24, as of Jun 2026.
What was Protalix BioTherapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Protalix BioTherapeutics, Inc.'s earnings per share (EPS) was $-0.08, compared with $0.04 in 2024.
How has Protalix BioTherapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Protalix BioTherapeutics, Inc.'s earnings per share (EPS) was highest in 2023 ($0.12) and lowest in 2021 ($-0.62).
How does Protalix BioTherapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Protalix BioTherapeutics, Inc.'s earnings per share (EPS) ($0.24) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.